KMT2C and cancer: Advancements in cancer exome sequencing studies have supported somatic KMT2C haploinsufficiency in acute myeloid leukemia, pancreatic ductal carcinoma, bile duct carcinoma, cutaneous squamous cell carcinoma, gastric adenocarcinoma, and hepatocellular carcinoma.9